SuperworthImageneBio IMA
- Market cap
- $47.9M
- PE
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/m
- one or more of the four quarters through 2026-06-30 missing
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Net margin
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Free cash flow yield
- n/m
- not a meaningful number
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $1.2M−82% | $659K−88% | n/a | n/a | $3.5M+195% | $0 | $800K | $0 | $0 | $0 | n/a | n/a | |
| R&D | $14.7M−22% | $14.3M−9% | $9.6M−38% | $9.8M−35% | $3.9M−74% | $4.6M−68% | $4M−58% | $5.7M−43% | $15.6M+301% | $3.3M−29% | $6M+48% | $6.7M+18% |
| SG&A | $6M+11% | $8.3M+68% | $6M+14% | $5.3M−0% | $1.7M−73% | $7.6M−8% | $2.8M−54% | $1.7M−68% | $11M+568% | $5.2M−31% | $6.1M+122% | $5.1M+200% |
| −$19.5M+9% | −$21.9M+45% | −$18.2M+18% | −$15.8M−14% | −$2M−90% | −$12.5M−43% | −$6M−67% | −$7.4M−54% | −$26.6M+1206% | −$8.5M−32% | −$12.1M+102% | −$11.8M+60% | |
| Pre-tax income | −$17.3M | −$19.7M | −$16.1M+13% | −$13.7M−20% | −$3.2M−82% | −$4.8M−76% | −$6.1M−62% | −$7.6M−45% | −$24.9M+681% | −$7.2M+50% | −$10.6M+75% | −$10.2M+34% |
| n/a | n/a | $27K | $62K | $0 | $13K | $28K+4% | $15K−76% | −$74K | −$276K | $10K−64% | $16K+7% | |
| Net income | −$17.3M+0% | −$19.5M+38% | −$16.1M+14% | −$13.7M−20% | −$3.2M−82% | −$4.8M−75% | −$6.1M−62% | −$7.6M−45% | −$24.8M+679% | −$6.9M+44% | −$10.6M+75% | −$10.2M+34% |
| −$4.80−17% | −$4.92+5% | −$3.96−15% | −$3.36−36% | −$2.58−46% | −$2.28−54% | −$3.80−4% | −$4.46+33% | −$2.91+13% | n/a | −$0.95−75% | −$0.63−86% | |
| 3.6M+20% | 4M+32% | 4M+33% | 4M+23% | 1.4M−61% | 4M+1% | 2.4M−40% | 2.4M−40% | 8.5M+509% | n/a | 11.2M+366% | 16.2M+572% |
EPS, diluted: 5 periods, Q4 FY20 to Q4 FY24: quarter's net income to common over its shares, to the cent.
Diluted shares: 4 periods, Q4 FY20 to Q4 FY24: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY21: share-days: the 12-month average less the 9-month, weighted by days. Q3 FY24 and Q3 FY25: not printed by the filing, worked out from its own lines.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Healthcare nearest ImageneBio's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| IMAImageneBio | $47.9M | n/m | n/a | n/m | n/m | n/m | |
| ATNMActinium Pharmaceuticals | $47.8M | 4.2× | 3.1× | n/m | n/m | n/m | |
| APTAlpha Pro Tech | $56.7M | 13.6× | 14.8× | 0.9× | +6% | 6.8% | |
| NEPHNephros | $38.3M | 22.1× | 28.4× | 1.9× | +24% | 8.4% | |
| SPROSpero Therapeutics | $64.6M | 10.1× | 9.5× | 1.4× | −3% | 15.7% | |
| LFVNLifevantage | $73.4M | 14.7× | 19.6× | 0.4× | −20% | 2.8% | |
| ICCCImmucell | $93.1M | 128× | 44.0× | 3.0× | +8% | 2.6% | |
| KEQUKewaunee Scientific | $94.9M | 11.9× | 13.7× | 0.3× | +5% | 3.0% | |
| PDEXPro DEX | $199.3M | 15.1× | 16.6× | 2.6× | +16% | 17.6% | |
| PLXProtalix BioTherapeutics | $205.5M | 11.1× | 34.2× | 2.5× | +30% | 23.5% | |
| NATRNatures Sunshine Products | $213.8M | 12.0× | 20.6× | 0.4× | +7% | 3.7% | |
| Peer median | $83.3M | 12.8× | 18.1× | 1.4× | +7% | 6.8% |
More on ImageneBio
Each number over time
Its groups
About
- Industry
- Biotechnology
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .